Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

American Society of Hematology (ASH) Annual Meeting and Exposition 2024

Aditi Shastri, Eric J Feldman, Alexander N. Starodub, Tatyana Feldman, Cristina P. Rodriguez, Zachary D. Epstein-Peterson, Don A Stevens, Adam J Olszewski, Auris O. Huen, Pierluigi Porcu, John C. Reneau, Stefan K. Barta, Enrica Marchi, Ahmad Mattour, Lauren Pinter-Brown, Rachelle Perea, Sean Donohue, Joyoti Dey, Sagar Agarwal, Rahul Karnik, Ashwin Gollerkeri, Alyssa Fasciano, Jared Gollob, Stephen D. Smith